Time filter

Source Type

PubMed | The Jordanian Pharmaceutical Manufacturing Co., University of Petra, Al - Hussein Bin Talal University and Al - Balqa Applied University
Type: Journal Article | Journal: Marine drugs | Year: 2016

An increasing interest has recently been shown to use chitin/chitosan oligomers (chito-oligomers) in medicine and food fields because they are not only water-soluble, nontoxic, and biocompatible materials, but they also exhibit numerous biological properties, including antibacterial, antifungal, and antitumor activities, as well as immuno-enhancing effects on animals. Conventional depolymerization methods of chitosan to chito-oligomers are either chemical by acid-hydrolysis under harsh conditions or by enzymatic degradation. In this work, hydrolysis of chitosan to chito-oligomers has been achieved by applying adsorption-separation technique using diluted HCl in the presence of different types of zeolite as adsorbents. The chito-oligomers were retrieved from adsorbents and characterized by differential scanning calorimetry (DSC), liquid chromatography/mass spectroscopy (LC/MS), and ninhydrin test.


Al Omari M.M.H.,The Jordanian Pharmaceutical Manufacturing Co. | Jaafari D.S.,The Jordanian Pharmaceutical Manufacturing Co. | Al-Sou'od K.A.,Al al-Bayt University | Badwan A.A.,The Jordanian Pharmaceutical Manufacturing Co.
Profiles of Drug Substances, Excipients and Related Methodology | Year: 2014

A comprehensive profile of moxifloxacin HCl with 198 references is reported. A full description including nomenclature, formulae, elemental analysis, and appearance is included. Methods of preparation for moxifloxacin HCl, its intermediates, and derivatives are fully described. In addition, the physical properties, analytical methods, stability, uses and applications, and pharmacology of moxifloxacin HCl are also discussed. © 2014 Elsevier Inc.


Al Omari A.A.,Al al-Bayt University | Al Omari M.M.,The Jordanian Pharmaceutical Manufacturing Company | Badwan A.A.,The Jordanian Pharmaceutical Manufacturing Company | Al-Sou'od K.A.,Al al-Bayt University
Journal of Pharmaceutical and Biomedical Analysis | Year: 2011

Guest-host interactions of candesartan cilexetil (CAND) with cyclodextrins (CyDs) have been investigated using phase solubility diagrams (PSD), X-ray powder diffractometry (XRPD), differential scanning calorimetry (DSC) and molecular mechanical modelling (MM). Estimates of the complex formation constant (K 11) show that the tendency of CAND (pK a=6.0) to complex with CyDs follows the order: β-CyD>HP-β-CyD>γ-CyD>α-CyD. Complex formation of CAND with β-CyD (ΔG°=-31.5kJ/mol) is largely driven by enthalpy change (ΔH°=-32.8kJ/mol) and slightly retarded by entropy change (ΔS°=-4.6J/molK). The HPLC results indicate that complex prepared by freeze drying method is chemically not stable due to the formation of amorphous CAND. Also it may suggest formulating CAND with β-CyD by kneading (dispersion) or co-evaporation (real inclusion complex) methods into capsule rather than compressed in tablets, where the compression enhances the instability of CAND. DSC thermograms for CAND/β-CyD complexes proved the formation of inclusion complexes with new solid phase. MM studies indicate the partial penetration of CAND into the β-CyD cavity. © 2010 Elsevier B.V.


PubMed | Al al-Bayt University, The Jordanian Pharmaceutical Manufacturing Co. and University of Petra
Type: | Journal: Profiles of drug substances, excipients, and related methodology | Year: 2015

A comprehensive profile of prasugrel HCl is reported herein with 158 references. A full description including nomenclature, formulae, elemental analysis, and appearance is included. Methods of preparation for prasugrel HCl, its intermediates, and derivatives are fully discussed. In addition, the physical properties, analytical methods, stability, uses and applications, and pharmacology of prasugrel HCl are also discussed.


PubMed | The Jordanian Pharmaceutical Manufacturing Co. and Chatham University
Type: Comparative Study | Journal: Marine drugs | Year: 2015

This study describes the preparation, characterization and performance of a novel excipient for use in oro-dispersible tablets (ODT). The excipient (Cop-CM) consists of chitin and mannitol. The excipient with optimal physicochemical properties was obtained at a chitin: mannitol ratio of 2:8 (w/w) and produced by roll compaction (RC). Differential scanning calorimetry (DSC), Fourier transform-Infrared (FT-IR), X-ray powder diffraction (XRPD) and scanning electron microscope (SEM) techniques were used to characterize Cop-CM, in addition to characterization of its powder and ODT dosage form. The effect of particle size distribution of Cop-CM was investigated and found to have no significant influence on the overall tablet physical properties. The compressibility parameter (a) for Cop-CM was calculated from a Kawakita plot and found to be higher (0.661) than that of mannitol (0.576) due to the presence of the highly compressible chitin (0.818). Montelukast sodium and domperidone ODTs produced, using Cop-CM, displayed excellent physicochemical properties. The exceptional binding, fast wetting and superdisintegration properties of Cop-CM, in comparison with commercially available co-processed ODT excipients, results in a unique multifunctional base which can successfully be used in the formulation of oro-dispersible and fast immediate release tablets.


Rashid I.,The Jordanian Pharmaceutical Manufacturing Co. | Daraghmeh N.,The Jordanian Pharmaceutical Manufacturing Co. | Daraghmeh N.,University of Greenwich | Al-Remawi M.,The Jordanian Pharmaceutical Manufacturing Co. | And 3 more authors.
Powder Technology | Year: 2010

The influence of the lubricant magnesium stearate (MgSt) on the powder and tablet properties of chitin-Mg silicate coprecipitate was examined and compared with lubricated Avicel® 200 and Avicel-Mg silicate coprecipitate. Crushing strength and disintegration time studies were conducted in order to evaluate tablet properties at different compression pressures. Lubrication of chitin-Mg silicate powder with MgSt was evaluated using a high speed rotary tablet press. The compactability and disintegration time of chitin-Mg silicate are unaffected by the possible deleterious action of up to 2% (w/w) MgSt. The deleterious effect of MgSt on Avicel® 200 compaction was found to be minimized when magnesium silicate was coprecipitated onto Avicel® 200. Lubrication of chitin-Mg silicate with MgSt does not enhance particle agglomeration, whereas the opposite is the case for Avicel® 200; the foregoing was ascertained by measurements of the fixed bulk density, constant powder porosity using Kawakita analysis and by the absence of variation in particle size distribution in the presence of up to 5% (w/w) MgSt. In the case of chitin-Mg silicate tablets the ejection force was greatly reduced at a compression speed of 150,000. tablet/h at a MgSt concentration of 0.5% (w/w). The physical properties and drug dissolution profile of ibuprofen tablets were found to be unaffected when chitin-Mg silicate was lubricated up to 5% (w/w) with MgSt. Optimal drug dissolution was attained for gemfibrozil tablets using 3% (w/w) MgSt when compared to a reference (Lopid tablets). © 2010 Elsevier B.V.


Patent
The Jordanian Pharmaceutical Manufacturing Co. | Date: 2013-10-30

The present invention relates to an oral liquid dosage formulation comprising: a) at least one pharmaceutically active compound; b) at least one divalent or trivalent salt; c) at least one pH regulating substance; and d) optionally at least one gelling agent, gelling aid, thickening agent, sweetener, preservative, stabilizing agent, coloring agent, flavoring agent, surfactant and/or emulsifier.


PubMed | The Jordanian Pharmaceutical Manufacturing Co.
Type: Journal Article | Journal: Marine drugs | Year: 2015

Despite the numerous uses of chitin and chitosan as new functional materials of high potential in various fields, they are still behind several directly compressible excipients already dominating pharmaceutical applications. There are, however, new attempts to exploit chitin and chitosan in co-processing techniques that provide a product with potential to act as a direct compression (DC) excipient. This review outlines the compression properties of chitin and chitosan in the context of DC pharmaceutical applications.


Patent
The Jordanian Pharmaceutical Manufacturing Co. | Date: 2011-05-11

The present invention relates to a pharmaceutical excipient comprising a mixture of sugar alcohol and chitin and/or chitin derivatives, a method for its preparation and use thereof.


Patent
The Jordanian Pharmaceutical Manufacturing Co. | Date: 2011-11-09

The present invention relates to a pharmaceutical excipient comprising a mixture of sugar alcohol and chitin and/or chitin derivatives, a method for its preparation and use thereof.

Loading The Jordanian Pharmaceutical Manufacturing Co. collaborators
Loading The Jordanian Pharmaceutical Manufacturing Co. collaborators